Displaying 151–160 of 856 results
Sep 8, 2022
Iveric Bio’s Zimura for Advanced Dry AMD Meets Endpoint in Second Phase 3 Clinical Trial
The company plans to seek FDA approval for the emerging therapy in first quarter of 2023
Aug 30, 2022
Foundation Insights Forum – August 12, 2022
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on August 12, 2022.
Aug 25, 2022
Belite Bio Launching Phase 3 Clinical Trial for Stargardt Disease Drug
The company’s drug is designed to reduce accumulation of toxins that cause vision loss.
Aug 15, 2022
Decades of Dedication Fighting for His Family and Himself
Dan Day is one of over ten people in his family, spanning six generations, affected with retinitis pigmentosa (RP). So to “get off the sidelines and join the fight” for himself and his family, Dan has dedicated over 25 years of service to the Foundation Fighting Blindness.
Aug 11, 2022
ProQR Seeking to Partner Ophthalmic Programs
The company is halting its clinical programs for LCA10 and USH2A as it seeks a new partner
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2022 (July 1, 2021–June 30, 2022)
Aug 10, 2022
Foundation Commits More Than $15 Million to 23 Promising Research Projects for Eradicating Retinal Diseases
Funding for the new grants was made possible by Foundation’s strong donor base and philanthropic partners
Jul 29, 2022
Progress toward a stem cell–based therapy for blindness
A multi-institutional effort led by researchers at the School of Veterinary Medicine is taking steps to develop an effective technique to regenerate photoreceptors cells and restore sight in people with vision disorders.
The Foundation Fighting Blindness is inviting you to share your vision-loss journey through written word, audio or video as a part of our October “Share Your Vision” campaign. Help your friends, family, and even people you don’t know, see the world through your eyes—because your story is powerful and unique.
Jul 25, 2022
Nanoscope Doses First Patient in Phase 2 Clinical Trial of its Optogenetic Therapy for Stargardt Disease
The emerging therapy is designed to restore vision for people with advanced retinal degenerative diseases